[1] 陈国建.影响乳腺癌远期生存率相关因素分析[J].广东医学(J Guangdong Med),2000,21(9):767-8. [2] 张军一,麦国丰,郑航,等.乳腺癌HER2、EGFR表达与生存期的相关性[J].第一军医大学学报,2003,23(10):1090-3.Zhang Jy,Mai GF,Zhang H,et al. Association between the survival time and high-expression of EGFR and HER-2 in breast cancer[J].J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2003,23(10):1090-3. [3] 麦国丰,郑航,罗荣城,等.乳腺癌HER2、孕激素受体表达与生存期相关性的研究[J].第一军医大学学报,2003,23(4):372-4.Mai GF,Zheng H,Luo RC,et al. Association of progesterone receptor and HER2 expressions with the survival time of patient with breast cancer[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2003,23(4):372-4. [4] 但汉雷,赵燕,张健,等.乳腺癌多药耐药细胞人中白细胞抗原和B7分子表达的体外调节[J].第一军医大学学报,2002,22(2):107-10.Dan HL,Zhao Y,Zhang J,et al. In vitroregulation of HLA and B7expression in multidrug-resistant breast cancer cells[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2002,22(2):107-10. [5] Moore B. A soluble protein characteristic of the nervous system[J].Biochem Biophys Res Commun,1965,19(9):739-44. [6] Schafer BW,Heizmann CW. The S100 family of EF-hand calciumbinding proteins:functions and pathology[J]. TIBS,1996,21(2):134-40. [7] Magenni DPs,Orchard GE. Malignant melanoma:Death by image and ignorance,diagnosis by surgical excision and laboratory investigation[J]. Br J Biomed Sci,1999,56(2):134-46. [8] Jackel A,Deichman M,Waldmann V,et al. S-100β protein in serum,a tumor marker in malignant melanoma-current state of knowledge and clinical experiences[J]. Hantarzt,1999,50(3):250-6. [9] Sherbet GV,Lakshmi MS. S100A4 (MTS1) calcium binding pwtein in cancer growth,invasion and metastasis[J]. Anticancer Res,1998,18(4A):2415-21. [10] 丁华野,皋岚湘,邓永江,等.S100,S100a和S100β蛋白在乳腺癌中的表达及诊断意义[J].中国组织化学和细胞化学杂志,1999,8(4):438-42.Ding HY,Gao LX,Deng YJ,et al. S100、S100α and S100β in breast carcinoma end its diagnostic significance[J]. Chin J Histochem Cytochem,1999,8(4):438-42. [11] Rydlander L,Ziegler E,Bergman T,et al. Molecular characterization of a tissue polypeptide specific antigen epitope and its relationship to human cytokeratin 18[J]. EurJ Biochem,1996,241(2):309-14. [12] 郑航,何本夫,罗荣城,等.组织多肽特异性抗原在乳腺癌中的临床研究[J].第一军医大学学报,2003,23(8):823-5.Zhaeng H,He BF,Luo RC,et al. Clinical study of serum tissue polypeptide-specific antigen in breast cancer[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2003,23(8):823-5. [13] Moll R,Franke WW,Schiller D,et al. The catalog of human cytokeratins:patterns of expression in normal epithelia,tumors and cultured cells-Review[J]. Cell,1982,31(1):11-24. [14] van Dalen A. TPS monitoring in metastatic breast cancer[J]. Int J Biol Markers,1999,14(1):45-8. [15] Bremer K,Eklund G,Bjorklund B. Notable relationship between the level of tumor marker TPS in serum end survival in breast cancer[J]. Anticancer Res,1996,16(2):905-9. |